FARON PHARMACEUTICALS OY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 127.5 GBX | 0.00% |
|
+8.51% | -58.20% |
| Apr. 16 | Faron Pharmaceuticals Oy Confirms Plans for the Coming Months | CI |
| Apr. 15 | Faron Pharmaceuticals reappoints former finance chief on interim basis | AN |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 134.4 | 136.4 | 169.4 | 202.7 | 241.9 | 107.1 | - | - |
| Enterprise Value (EV) 1 | 130.2 | 132.4 | 163 | 206.8 | 247.9 | 137.7 | 64.85 | 107.1 |
| P/E ratio | -10 x | -7.86 x | -7.58 x | -6.52 x | -7.33 x | -4.85 x | -9.6 x | -4.8 x |
| Yield | - | - | - | - | - | 1.01% | - | - |
| Capitalization / Revenue | - | - | - | - | - | 7.44 x | 2.74 x | 8.34 x |
| EV / Revenue | - | - | - | - | - | 9.56 x | 1.66 x | 8.34 x |
| EV / EBITDA | -10.1 x | -8.09 x | -7.84 x | -7.62 x | -8.78 x | -39.7 x | -24.7 x | -3.51 x |
| EV / FCF | - | - | - | -8.85 x | -10.4 x | 5.45 x | -2.19 x | -3.07 x |
| FCF Yield | - | - | - | -11.3% | -9.65% | 18.3% | -45.6% | -32.5% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 43,291 | 46,897 | 53,232 | 59,805 | 68,787 | 72,007 | - | - |
| Reference price 2 | 3.104 | 2.909 | 3.182 | 3.389 | 3.516 | 1.488 | 1.488 | 1.488 |
| Announcement Date | 3/20/20 | 3/25/21 | 3/25/22 | 3/3/23 | 3/13/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | 14.4 | 39.09 | 12.85 |
| EBITDA 1 | -12.86 | -16.37 | -20.8 | -27.13 | -28.22 | -3.466 | -2.626 | -30.55 |
| EBIT 1 | -13.1 | -16.65 | -21.11 | -27.43 | -28.57 | -3.733 | -3.033 | -31.55 |
| Operating Margin | - | - | - | - | - | -25.93% | -7.76% | -245.53% |
| Earnings before Tax (EBT) 1 | -13.25 | -16.94 | -21.18 | -28.73 | -30.94 | -5.7 | -4.6 | -33.95 |
| Net income 1 | -13.26 | -16.95 | -21.19 | -28.73 | -30.94 | -6.367 | -4.6 | -33.95 |
| Net margin | - | - | - | - | - | -44.21% | -11.77% | -264.2% |
| EPS 2 | -0.3100 | -0.3700 | -0.4200 | -0.5200 | -0.4800 | -0.3067 | -0.1550 | -0.3100 |
| Free Cash Flow 1 | - | - | - | -23.38 | -23.93 | 25.25 | -29.6 | -34.85 |
| FCF margin | - | - | - | - | - | 175.35% | -75.72% | -271.21% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | 0.0150 | - | - |
| Announcement Date | 3/20/20 | 3/25/21 | 3/25/22 | 3/3/23 | 3/13/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 | 2025 S1 | 2025 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | -6.568 | -7.015 | -9.356 | -10.28 | - | -13.21 | -13.91 | -12.64 | -15.58 | -13.9 | -15.7 | - | - |
| EBIT 1 | -6.758 | -7.145 | -9.509 | -10.42 | -10.68 | -13.36 | -14.06 | -12.81 | -15.76 | -14.1 | -15.9 | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -6.84 | -7.343 | -9.593 | -10.55 | -10.62 | -13.1 | -15.63 | -13.73 | -17.21 | -15.3 | -17.2 | - | - |
| Net income 1 | -6.85 | -7.343 | -9.603 | -10.56 | -10.63 | -13.12 | -15.61 | -13.73 | -17.21 | -15.3 | -17.2 | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.1600 | -0.1600 | -0.2200 | -0.2100 | -0.2100 | -0.2500 | -0.2700 | -0.2200 | -0.2600 | -0.2100 | -0.2100 | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/20/20 | 9/24/20 | 3/25/21 | 8/26/21 | 3/25/22 | 8/25/22 | 3/3/23 | 8/29/23 | 3/13/24 | - | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 4.11 | 6.02 | 30.6 | - | - |
| Net Cash position 1 | 4.24 | 3.99 | 6.42 | - | - | - | 42.3 | - |
| Leverage (Debt/EBITDA) | - | - | - | -0.1516 x | -0.2134 x | -8.829 x | - | - |
| Free Cash Flow 1 | - | - | - | -23.4 | -23.9 | 25.3 | -29.6 | -34.9 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share 2 | -0.3200 | - | -0.4400 | -0.4200 | - | -0 | 0 | - |
| Capex 1 | - | 0.01 | 0.01 | 0.39 | 0.12 | 0.1 | 0.47 | 1.7 |
| Capex / Sales | - | - | - | - | - | 0.69% | 1.19% | 13.23% |
| Announcement Date | 3/20/20 | 3/25/21 | 3/25/22 | 3/3/23 | 3/13/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.488
EUR
Average target price
11.6
EUR
Spread / Average Target
+680.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -58.20% | 114M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- FARN Stock
- Financials Faron Pharmaceuticals Oy
